Schlame Michael MD is categorized under Pro Standards Review Organizations in New York City, NY and active since 2007.
Schlame Michael MD was established in 2007, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Pro Standards Review Organizations business, which does work in the B2B market, and is classified as a Pro Standards Review Organizations, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Michael Schlame at the company’s single location by writing to 550 1st Avenue, New York City, New York NY 10016 or by phoning (212) 263-7300. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Schlame Michael MD |
Contact Person: | Michael Schlame |
Address: | 550 1st Avenue, New York City, New York 10016 |
Phone Number: | (212) 263-7300 |
Website Address: | cancer.med.nyu.edu |
Annual Revenue (USD): | $500.000 to $999.999 |
Founded: | 2007 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Pro Standards Review Organizations |
SIC Code: | 8621 |
NAICS Code: | 6211110 |
Share This Business: |
Schlame Michael MD was started in 2007 to provide professional Pro Standards Review Organizations under the SIC code 8621 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Michael Schlame for inquiries that concern Schlame Michael MD by calling the company number (212) 263-7300, as your correspondence is most welcome. Additionally, the physical location of the single location of Schlame Michael MD can be found at the coordinates 40.74283,-73.9742 as well as the street address 550 1st Avenue in New York City, New York 10016.
For its online presence, you may visit Schlame Michael MD’s website at cancer.med.nyu.edu and engage with its social media outlets through on Twitter and on Facebook.